Market Place
Sourcing Support
Alexion, AZ Rare Disease, Completes Acquisition of LogicBio Therapeutics
16 Nov 2022 //
BUSINESSWIRE
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio
16 Nov 2022 //
BUSINESSWIRE
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
PRNEWSWIRE
Alexion, AstraZeneca Rare Disease to Acquire LogicBio
04 Oct 2022 //
PRNEWSWIRE
LogicBio Therapeutics Announces Pre-Clinical Results for mLB-001 Published
21 Sep 2022 //
APNEWS
LogicBio Announces Results for mLB-001 Published in Journal PLOS ONE
21 Sep 2022 //
PRNEWSWIRE
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
PRNEWSWIRE
LogicBio Therapeutics Reports First Quarter 2022 Financial Results
16 May 2022 //
PRNEWSWIRE
LogicBio`s sun and shares rise after FDA releases clinical hold
10 May 2022 //
FIERCEBIOTECH
FDA puts LogicBio genome editing therapy trial on hold
03 Feb 2022 //
FIERCEBIOTECH
LogicBio Therapeutics Provides Business Updates
22 Dec 2021 //
PRNEWSWIRE
LogicBio Therapeutics Reports Q3 2021 Financial Results
15 Nov 2021 //
PRNEWSWIRE
Intellia, LogicBio fuel hope for in vivo gene editing: report
26 Oct 2021 //
FIERCEBIOTECH
LogicBio Announces Successful Repopulation of Diseased Livers in Mice
21 Oct 2021 //
PRNEWSWIRE
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating
18 Oct 2021 //
PRNEWSWIRE
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society
12 Oct 2021 //
PRNEWSWIRE
LogicBio to Participate in the 2021 Cantor Virtual Global Healthcare Conference
24 Sep 2021 //
PRNEWSWIRE
LogicBio Announces Presentation of Retrospective Study of Disease
03 May 2021 //
PRNEWSWIRE
LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement
27 Apr 2021 //
BIOSPACE
LogicBio Therapeutics Announces Clinical and Corporate Updates
27 Apr 2021 //
PRNEWSWIRE
LogicBio Reports Full Year 2020 Financial Results and Provides Business
15 Mar 2021 //
PRNEWSWIRE
LogicBio Announces Extension Of Collaboration With Children`s Medical Research
07 Jan 2021 //
PRNEWSWIRE
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001
04 Nov 2020 //
GLOBENEWSWIRE
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
01 Oct 2020 //
GLOBENEWSWIRE
Locus Biosciences signs contract with BARDA to advance $144 million
30 Sep 2020 //
PRNEWSWIRE
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
30 Sep 2020 //
GLOBENEWSWIRE
LogicBio readies equity offering
30 Sep 2020 //
SEEKING ALPHA
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001
10 Aug 2020 //
GLOBENEWSWIRE
LogicBio Therapeutics to Present New Data on GeneRide™ Platform
11 May 2020 //
GLOBENEWSWIRE
LogicBio rocked by FDA clinical hold on genome editing trial
12 Feb 2020 //
FIERCE BIOTECH
